A wide variety of drugs can cause psychosis that is transient once the drug is removed. Some drugs cause such a transient, drug-induced psychosis in most people who take them (e.g., LSD and PCP), and other drugs cause psychosis only in a minority of susceptible patients (e.g., cannabis). This chapter reviews common drugs associated with psychosis: alcohol and sedative (during intoxication and withdrawal), cannabis, stimulants, LSD and hallucinogens, and PCP. The difficulties in making a diagnosis of drug-induced psychosis vis-à-vis a primary psychotic disorder are discussed, particularly as more potent designer drugs are easily available today, and psychosis can be prolonged. The public health ramifications of high-potency cannabis as a risk factor for schizophrenia are emphasized.
KeywordsDrug-induced psychosis Diagnosis Treatment Urine drug testing Alcohol Sedative Cannabis Stimulants Methamphetamine LSD Hallucinogens PCP Ketamine Medication-induced psychosis Toxins
- 1.The-Philosophy.com. Jim Morrison Available from: https://www.the-philosophy.com/jim-morrison-quotes. Accessed on 7/1/2019.
- 13.McCain CF, Namey LB, Freudenreich O. Lamotrigine cross-reactivity with phencyclidine in rapid urine toxicology in a research study. Prim Care Companion CNS Disord. 2018;20(4) pii. 17l02192.Google Scholar
- 30.The Guardian. Basel in the spotlight: the city that learned to love LSD. 2018 Available from: https://www.theguardian.com/cities/2018/apr/19/basel-in-the-spotlight-the-city-that-learned-to-love-lsd-albert-hofmann. Accessed on 7/1/2019.
- 32.Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8Google Scholar
- 34.Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620–30.CrossRefGoogle Scholar
- 36.Freudenreich O, Brown HE, Holt DJ. Psychosis and schizophrenia. In: Stern TA, Fava M, Wilens TE, Rosenbaum JF, editors. Massachusetts General Hospital comprehensive clinical psychiatry. 2nd ed. Philadelphia: Elsevier; 2016. p. 307–23.Google Scholar
- Huxley A. The doors of perception. New York: Harper & Brothers; 1954. – The English writer Huxley describes his psychedelic experiences under mescaline. His philosophical insights make this book worth reading today, particularly as psychiatry rediscovers the therapeutic values of mind-altering drugs. While you may never use psychedelic substances yourself, the book may open your mind (sorry about this pun which is intended) to the limits of day-to-day experiences.Google Scholar
- Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15:195–204. – A good overview over the changes in potency of cannabis products and the unresolved public health questions.CrossRefGoogle Scholar
- Nour MM, Carhart-Harris RL. Psychedelics and the science of self-experience. Br J Psychiatry. 2017;210:177–9. – A topic that I did not cover in detail: the therapeutic use of currently mostly illicit psychedelic substances. Psilocybin for example is being tested for use in cancer patients with depression and existential concerns.CrossRefGoogle Scholar